

PHARMACY POLICY STATEMENT

Georgia Medicaid

DRUG NAME	Sovaldi (sofosbuvir)
BILLING CODE	Must use valid NDC code
BENEFIT TYPE	Pharmacy
SITE OF SERVICE ALLOWED	Home
COVERAGE REQUIREMENTS	Prior Authorization Required (Non-Preferred Product) Alternative preferred products include Mavyret and Sofosbuvir/velpatasvir (generic for Epclusa) QUANTITY LIMIT— 28 for a 28 day supply
LIST OF DIAGNOSES CONSIDERED NOT MEDICALLY NECESSARY	Click Here

Sovaldi (sofosbuvir) is a **non-preferred** product and will only be considered for coverage under the **pharmacy** benefit when the following criteria are met:

Members must be clinically diagnosed with one of the following disease states and meet their individual criteria as stated.

HEPATITIS C (without cirrhosis or with compensated cirrhosis (Child-Turcotte-Pugh Class A))

For **initial** authorization:

1. Member who is 12-17 years of age must tried and failed course of treatment with Mavyret (Dates and HCV RNA values must be documented in chart notes) OR if member is 18 years of age and older must tried and failed courses of treatment with Sofosbuvir/velpatasvir (generic for Epclusa) and Mavyret (Dates and HCV RNA values must be documented in chart notes); AND
2. Member is treatment-naïve or treatment-experienced with genotype 2 or 3 (laboratory documentation required); AND
3. Medication must be used in combination with ribavirin; AND
4. Medication must be prescribed by a board certified hepatologist, gastroenterologist, infectious disease specialist or a nurse practitioner working with the above specialists; AND
5. Member's documented viral load taken within 6 months of beginning therapy and submitted with chart notes; AND
6. Member has documented current monthly negative urine drug and alcohol screens for 3 consecutive months (laboratory documentation required); AND
7. Member does **not** have moderate to severe hepatic impairment (Child-Turcotte-Pugh B and C).
8. **Dosage allowed:** Sovaldi (one tablet once daily) + ribavirin for 12 weeks for genotype 2; Sovaldi (one tablet once daily) + ribavirin for 24 weeks for genotype 3.

Note: Member's life expectancy must be no less than one year due to non-liver related comorbidities.

If member meets all the requirements listed above, the medication will be approved for 12-24 weeks, see Appendix below.

For **reauthorization**:

1. Member is treatment experienced without cirrhosis or is treatment-experienced with compensated cirrhosis (Child-Turcotte-Pugh Class A); AND
2. Member must be in compliance with all other initial criteria; AND
3. Member is compliant with drug therapy regimen by paid pharmacy claims; AND

4. Member's HCV RNA greater than or equal to lower limit of quantification (LLOQ) of 25 IU per mL with 2 consecutive values during the post-treatment period after achieving HCV RNA less than LLOQ at end of treatment. Dates and HCV RNA values must be documented in chart notes; AND
5. Member must have a documented reason of treatment failure of previously tried medication.

If member meets all the reauthorization requirements listed above, the medication will be approved for an additional 12-24 weeks.

CareSource considers Sovaldi (sofosbuvir) not medically necessary for the treatment of the diseases that are not listed in this document.

DATE	ACTION/DESCRIPTION
05/09/2017	New policy for Sovaldi created. Criteria coverage was adjusted for age, alternative products were indicated. Hep B test requirement was added. Drug and alcohol screens for 3 consecutive months required for all regardless of abuse history. Evidence of liver fibrosis exceptions was expanded. Reauthorization requirement of 2 consecutive values of HCV RNA \geq 25 IU per mL during the post-treatment period and documented reason of treatment failure were added.
06/08/2017	Fibrosis stage 2 and above covered.
11/22/2017	Substance abuse program information is no longer required. Criterion on absence of moderate to severe liver impairment was added.
12/07/2017	Criterion of "life expectancy not less than one year due to non-liver related comorbidities" removed from criteria and added in a form of the note. Hepatitis B testing is no longer required.
12/21/2017	Fibrosis score requirement was removed.
05/01/2019	Sofosbuvir/velpatasvir (generic for Epclusa) trial added for adult members; Mavyret trial added for members 12 -17 years of age.

References:

1. Sovaldi [package Insert]. Foster City, CA: Gilead Sciences, Inc.; November, 2017.
2. Hepatitis C Information | Division of Viral Hepatitis | CDC. (2015, May 31). Retrieved from <https://www.cdc.gov/hepatitis/hcv/index.htm>.
3. American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD) and Infectious Diseases Society of America (IDSA). HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C; 2017. Available at: <https://www.hcvguidelines.org/>.
4. Afdhal, N. (2012). Fibroscan (Transient Elastography) for the Measurement of Liver Fibrosis. *Gastroenterology & Hepatology*, 8(9), 605-607.

Effective date: 07/01/2019

Revised date: 05/01/2019

Genotype	Pediatric Patient Population 12 Years of Age and Older or Weighing at Least 35 kg	Regimen and Duration
Genotype 2	Treatment-naïve and treatment-experienced without cirrhosis or with compensated cirrhosis (Child-Pugh A)	Sovaldi + ribavirin 12 weeks
Genotype 3	Treatment-naïve and treatment-experienced without cirrhosis or with compensated cirrhosis (Child-Pugh A)	Sovaldi + ribavirin 24 weeks